Latest News

Leadership change puts BioCryst’s R&D focus in the spotlight BioCryst Pharmaceuticals (BCRX) recently named Sandeep M. Menon as Chief Research and Development Officer, putting fresh attention on how new leadership could shape the company’s rare disease pipeline and longer term growth plans. See our latest analysis for BioCryst Pharmaceuticals. The appointment of Dr. Menon comes at a time when BioCryst’s share price has a 90 day share price return of 42.9% and a 1 year total shareholder return...

Q1 beat on revenue and profits despite softer egg prices Cal-Maine Foods (CALM) reported Q1 revenue and profit above analyst expectations, a key development for shareholders given the pressure from lower egg prices and questions about the durability of recent earnings. See our latest analysis for Cal-Maine Foods. At a share price of $76.31, Cal-Maine Foods has seen a 1 day share price return of 1.72%, while its 1 month share price return of 11.90% decline contrasts with a 5 year total...

If you are wondering whether NOW at ₱0.57 is a bargain or a value trap, you are in the right place for a clear look at what the current price might actually reflect. The share price has returned 1.8% over the last 7 days, while the stock is down 1.7% over 30 days, off 18.6% year to date, but up 42.5% over 1 year and still 63.7% and 80.3% lower over 3 and 5 years respectively. Recent coverage has focused less on short term headlines and more on how investors are reassessing companies like NOW...

Cosa Resources Corp. recently reported intersecting anomalous radioactivity in multiple drill holes and completing the winter 2026 program at the Murphy Lake North Project, a uranium exploration joint venture with Denison Mines in the eastern Athabasca Basin. The shallow, open-ended radioactive zones along a major structural corridor point to meaningful exploration upside for Denison’s portfolio through this partnership-driven discovery work. We’ll now examine how this exploration success at...

Wondering if Globus Medical at around US$92.76 is offering fair value or if the price is getting ahead of itself? This breakdown will help you frame that question using clear valuation checks. The stock has returned 1.5% over the past week, 5.2% over the last month, 6.3% year to date, 30.6% over 1 year, 59.8% over 3 years and 30.6% over 5 years, which may shape how you think about both upside potential and risk. Recent coverage of Globus Medical has focused on its role in the wider medical...

With Yum China Holdings up 19.9% over the past year, many investors are asking a simple question: is the current share price of US$48.54 offering good value, or is most of the upside already reflected? The picture is mixed in the shorter term, with a 3.2% decline over the last 7 days and a 10.1% decline over the last 30 days, while year to date the stock is roughly flat at a 0.8% gain. It is still ahead over 3 years, and lower over 5 years, with returns of 19.1% and 11.5% declines...

CRA International (CRAI) is back in focus after recent share price swings. The stock has been roughly flat over the past year but has shown a negative move over the past 3 months. See our latest analysis for CRA International. Recent trading tells a mixed story, with a 4.1% 30 day share price return set against a 23.1% decline over 90 days, while the 5 year total shareholder return of 126.2% reflects much stronger long term performance. If CRA International’s recent swings have you thinking...

Spire (NYSE:SR) agreed to sell its natural gas storage assets in Wyoming and Oklahoma to I Squared Capital. The transaction shifts Spire's portfolio toward regulated natural gas utilities and supports funding for its recent Nashville acquisition. The move reflects a material change in business mix and risk profile that has not yet been widely discussed. Spire is primarily a regulated natural gas utility, and this agreement to sell Wyoming and Oklahoma storage assets tightens that focus. By...

If you are wondering whether Brunswick at around US$77 per share still offers value, you are not alone, especially after the stock's strong run over the past year. The share price is at US$77.33, with a 7 day return of a 0.8% decline, 30 day return of 8.0%, year to date return of 1.9% and 1 year return of 81.2%, while the 3 year and 5 year returns sit at a 3.3% decline and a 16.8% decline. Recent moves in the stock have drawn more attention to how the market is currently pricing Brunswick...

Earlier this week, Gilead Sciences announced expanded collaborations with the U.S. State Department, PEPFAR, and The Global Fund to widen access to its twice-yearly injectable HIV prevention medicine, lenacapavir, targeting up to an additional 1 million people through 2028 in high-incidence, resource-limited regions. This move not only extends Gilead’s reach in global HIV prevention but also highlights how no-profit pricing and planned generic rollout could reshape its role in public health...

Tencent Holdings (SEHK:700) has launched a major family focused initiative on positive video gaming in partnership with Games for Change. The new Raising Good Gamers programme introduces resources for parents, educators, and young players, supported by global research on gaming and wellbeing. The effort is designed to influence how families and society talk about games, with plans for international reach beyond Tencent’s home market. Tencent Holdings, trading at around HK$510.5, is adding a...

Over the last 7 days, the United States market has experienced a significant decline of 29%, contributing to an overall drop of 82% over the past year, though earnings are forecast to grow by 16% annually. In such volatile conditions, identifying stocks that are undervalued relative to their intrinsic value can present opportunities for investors seeking potential long-term gains.

Wesdome Gold Mines Ltd. recently reported first-quarter 2026 operating results, producing 45,303 ounces of gold, slightly below the 45,692 ounces delivered a year earlier, while also progressing throughput at Eagle River and stabilizing operations at Kiena. Alongside these operational updates, the company has nearly completed its normal course issuer bid with 2.1 million shares repurchased year-to-date, reinforcing management’s confidence in Wesdome’s balance sheet and long-term plans. Now...

In recent days, CoreWeave completed and expanded multiple private offerings of its 9.750% senior notes due 2031, raising an additional US$1.00 billion at a price of 102% on top of an earlier US$1.75 billion tranche, while also issuing US$3.50 billion of 1.75% convertible notes due 2032. Alongside these financings, new multi-year AI cloud agreements with Meta Platforms, Anthropic and a roughly US$6.00 billion commitment from Jane Street, plus Jane Street’s US$1.00 billion equity purchase, are...

If you are wondering whether Gap's share price still offers value after a strong run, or if most of the opportunity is already priced in, this article breaks down what the current market price might be implying about the company. Gap's stock has seen a 40.3% return over the last year and 209.3% over the last 3 years, while the most recent 7 day return of a 1.1% decline sits against a 9.4% gain over the last 30 days and a 3.5% return year to date. Recent headlines around Gap have focused on...

Western Midstream Partners triggered stock overview Western Midstream Partners (WES) has drawn fresh attention after recent trading, with the units closing at US$40.85. Investors are weighing this level against the partnership’s income profile and longer term return record. See our latest analysis for Western Midstream Partners. The latest move to US$40.85 comes after a modest 1 day share price return of 1.09%, set against a slightly weaker 30 day share price return of 1.47%. At the same...

Over the last 7 days, the United States market has experienced a significant drop of 29%, contributing to an overall decline of 82% over the past year. In light of these challenging conditions, identifying growth companies with substantial insider ownership can be particularly appealing as it often indicates confidence in future performance and alignment with shareholder interests.

If you are trying to figure out whether Compass at around US$7.30 is a bargain or just fairly priced, the key is to understand what the current share price actually reflects. The stock has been through a mixed spell, with a 1% gain over the last 7 days, a 14.4% decline over 30 days, a 30.5% decline year to date, a very large 3 year return, and a 0.1% return over the past year. This combination can change how investors think about both potential upside and risk. Recent headlines around...

DHT Holdings recently released a business update reporting strong preliminary first-quarter 2026 time charter equivalent earnings, with its VLCCs achieving high spot-market rates and a large portion of second-quarter revenue days already fixed at elevated charter levels, pointing to firm trading conditions in the crude tanker market. This combination of robust realized earnings and substantial forward booking at high rates provides clearer visibility on near-term cash generation and how...

Over the last 7 days, the United States market has experienced a significant downturn, dropping 29%, and is down 82% over the past year, though earnings are forecast to grow by 16% annually. In challenging market conditions like these, identifying stocks with strong financial fundamentals becomes crucial for investors seeking potential opportunities. Although "penny stocks" may seem like an outdated term, they continue to represent smaller or newer companies that can offer both affordability...

If you are wondering whether Fluor's current share price lines up with its underlying worth, this breakdown will help you connect the recent share performance with what the fundamentals may be implying. The stock recently closed at US$47.88, with returns of 7.2% over 30 days, 14.8% year to date and 41.0% over 1 year. This puts valuation questions front and center for many investors. Over longer periods, Fluor has recorded returns of 60.0% over 3 years and 122.9% over 5 years. This provides...

Earlier this month, Annexon, Inc. presented at the 25th Annual Needham Virtual Healthcare Conference, where CEO Douglas E. Love outlined the company’s upcoming clinical and regulatory milestones. A key takeaway was management’s description of 2026 as a “win year,” highlighting expected GBS regulatory filings, a Phase III geographic atrophy readout, and proof-of-concept data for ANX1502, all supported by a cash runway projected into the second half of 2027. We’ll now look at how this “win...

Over the last 7 days, the United States market has experienced a significant drop of 29%, and over the past year, it has declined by 82%, though earnings are expected to grow by 16% per annum in the coming years. In this challenging environment, identifying stocks with strong fundamentals and growth potential can be key to uncovering hidden gems that may offer promising opportunities.

Ramelius Resources Limited recently participated in the Mining Forum Europe 2026 in Zürich, where Chief Financial Officer Darren J. Millman delivered a company presentation. This investor-facing conference appearance offers the market fresh insights into Ramelius’s financial position, capital allocation priorities, and growth plans in the gold sector. We’ll now examine how the CFO’s Mining Forum Europe presentation may influence Ramelius’s investment narrative and expectations for future...